Latest GeneThera Inc. Stories
WESTMINSTER, Colo., June 25, 2012 /PRNewswire/ -- GeneThera Inc. (OTCQB: GTHR) is pleased to announce that Applied Genetics, GeneThera's majority owned subsidiary, has initiated commercial operation of its molecular diagnostic laboratory based in Monterrey, Mexico. Applied Genetics molecular diagnostic laboratory is the first molecular laboratory in Mexico, to date, which is capable to detect Johne's disease at the molecular level in milk, blood, and feces from dairy cows, goats and...
WESTMINSTER, Colo., May 16, 2012 /PRNewswire/ -- GeneThera, Inc. (OTCQB: GTHR) announced today that Applied Genetics, GeneThera's majority owned subsidiary, signed a research and test validation agreement with Universidad National Autonoma de Mexico (UNAM). Scope of the agreement is to validate GeneThera proprietary Johne's disease (JD) HerdCheck Field Collection System (FCS) Molecular Assay in Mexico. Dr. Tony Milici, interim president of Applied Genetics and CEO of GeneThera,...
WESTMINSTER, Colo., Feb. 22, 2012 /PRNewswire/ -- GeneThera Inc. (OTCQB: GTHR) announced today that Applied Genetics; GeneThera's majority owned subsidiary, has entered in an exclusive marketing and sales agreement with Nutricion Avanzada S.A. to market GeneThera's proprietary Johne's Disease HerdCheck(TM) Field Collection System (FCS) Molecular Assay. Under the terms of the agreement, Nutricion Avanzada will have exclusive rights to purchase and distribute the FCS in Mexico."This...
WESTMINSTER, Colo., Jan. 25, 2012 /PRNewswire/ -- GeneThera, Inc. (OTCQB: GTHR) announced today that it has acquired a majority ownership of Applied Genetics, a molecular diagnostic company based in Monterrey, Mexico. Applied Genetics is a molecular diagnostic company that focuses on commercializing molecular testing for Johne's disease in Mexico. This acquisition is part of a broader strategy aimed at quickly initiating Applied Genetics revenue-generating operation. Dr. Tony...
Results from Pharma Finance 2009 ARVADA, Colo., June 16 /PRNewswire-FirstCall/ -- GeneThera, Inc. (OTC: GTHR.PK). GeneThera, as a service and responsibility to our shareholders, is addressing our recent events. GeneThera Inc. recently attended Pharma Finance 2009, a Biotechnology, Medical Devices, and world public and private Finance Conference in Rome, Italy on June 4-5. Pharma Finance is an international event addressing new technologies for Life Sciences, concentrating on...
WHEAT RIDGE, Colo., Oct. 27 /PRNewswire-FirstCall/ -- GeneThera, Inc. (Pink Sheets: GTHR), announced today that it has signed an agreement with STC.UNM (STC), the technology-transfer arm of the University of New Mexico (UNM), giving GeneThera an option to a license to worldwide development and distribution rights to a vaccine developed at UNM's Health Sciences Center that is designed to significantly inhibit the carriage and shedding of the E. coli bacteria in cattle. The technology...
GeneThera, Inc. (PINKSHEETS: GTHR) announced today that it is in negotiations with the University of New Mexico for world wide development and distribution rights to a vaccine developed there that is designed to significantly inhibit the carriage and shedding of the E.coli bacteria in cattle. According to University sources, the vaccine is comprised of "Live Attenuated Bacterial Vaccine to Reduce or Inhibit Carriage and Shedding of Enterohemorrhagic Escherichia Coli in Cattle" In the most...
GeneThera, Inc. (PINKSHEETS: GTHR) announced today that has tendered a new offer for the acquisition of Oxford Biomedica Plc. Commenting on the news GeneThera Chairman Dr. Tony Milici, M.D., Ph.D. stated, "We carefully evaluated Oxford Biomedica's present situation from a management, scientific and equity prospective. Based on our analysis, we decided to resubmit our previous rejected offer at a higher price per share. We strongly believe that GeneThera may indeed be in the position, by...
GeneThera, Inc. (PINKSHEETS: GTHR), a molecular biotechnology company focused on the detection and treatment of disease in live animals using state-of-the-art technology, is pleased to issue this informational release to its shareholders. In the past month, GeneThera has made important progress in its long-term goal to become a profitable, dynamic biotech business. The increased value of our stock after last month's reverse split has positioned GeneThera to seriously consider a strategic...
GeneThera, Inc.'s (PINKSHEETS: GTHA) CEO Dr. Tony Milici, M.D., Ph.D. wanted to provide an update on the company's recent developments to its loyal shareholders and investment community in the United States and abroad. Firstly, none of the fundamentals has changed within the company. In fact, opportunities are increasing, especially with respect to recent pressure from the twenty-four members of Congress in a letter dated June 12, 2008, to Secretary of Agriculture Edward Schafer to allow...
